Trial Search Results

Seal, Stopping Eczema and Allergy Study

This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 10 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) or moisturizer and proactive use of fluticasone propionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Kari Christine Nadeau, MD, PhD

Collaborator: King's College London

Stanford Investigator(s):

Intervention(s):

  • Combination Product: Tri-lipid skin barrier cream (Epiceram)
  • Combination Product: Fluticasone propionate Cream 0.05%
  • Combination Product: Moisturizer
  • Other: Standard of Care

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   1. Participants who develop early onset visible dry skin or atopic dermatitis up to and
   equal to 10 weeks of age.

   2. Stated willingness to comply with all study procedures and availability for the
   duration of the study

   3. In good general health as evidenced by medical history

   4. No known adverse reaction to any of the study medications, their components or
   excipients

Exclusion Criteria:

   1. Infants <3kg body weight

   2. Infants with a chronic disease requiring therapy (e.g. heart disease, diabetes,
   serious neurological defects, immunodeficiency)

   3. Known moderate to severe cutaneous skin disorder other than AD, including but not
   limited to cutaneous mastocytosis, bullous skin disease, pustular skin disease,
   neonatal HSV, aplasia, and albinism

   4. Parents or guardians unwilling to sign consent

   5. Current participant or participation since birth in any interventional study

   6. Investigator or designee considers that the participant or parent/guardian would be
   unsuitable for inclusion in the study (for ex/ long stay in NICU)

   7. A course of antibiotics in infant within 7 days of enrollment

Ages Eligible for Study

N/A - 10 Weeks

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kari Nadeau, M.D., PhD
650-724-0293